If a drug is developed mostly with taxpayer-funded research money through the NIH or other Federal grants, the taxpayers should get some kind of royalty and that is a question that we have not resolved. Frankly, we may need some help from the Secretary of Health and Human Services, the people at NIH, the National Science Foundation, as well as some of the folks at the Patent Office. I am delighted to hear that we may have a hearing on this whole issue in the Committee on Energy and Commerce, and I hope we can bring some of those people in to explain to us as policymakers and to the people of the United States how it is that we can get shorted on both ends. In other words, we pay for the research and we pay exorbitantly high prices for the drugs relative to the rest of the world.
Gilbert Gutknecht: “If a drug is developed mostly with taxpayer-funded research money through the NIH or other Federal grants, the taxpayers…”
Editor's note · Context
Discussing the issue of taxpayer funding for drug development and the need for royalties for taxpayers.
Share
More from Gilbert Gutknecht
I have been so blessed to serve in this great body for the last 12 years. I wanted to reflect a little bit about what it was like when I first ran for Congress, what it was like during those heady days, some of the highs and lows, some of…
I was talking about the Kurds, and I think every part of the trip, in my opinion, was a highlight. I hate to say one was more important than the other. But what I had said before you came in, Congressman Hoekstra, was that I was so…
That is exactly what Melvin Laird said about Vietnam. That is why it was important to turn Vietnam, as soon as possible, back to the Vietnamese people. He said the greatest mistake was the Americanization of the Vietnam War. I think that…
I rise again tonight on the floor of the House to talk about the issue of prescription drugs and how much Americans pay relative to consumers in the rest of the industrialized world. What we have on this chart are the prices effective…





